Regeneron Pharmaceuticals, Inc. vs Xencor, Inc.: Efficiency in Cost of Revenue Explored

Biotech Giants' Cost Efficiency: Regeneron vs. Xencor

__timestampRegeneron Pharmaceuticals, Inc.Xencor, Inc.
Wednesday, January 1, 201420501800018516000
Thursday, January 1, 201539270900034140000
Friday, January 1, 201629969400051872000
Sunday, January 1, 201739706100071772000
Monday, January 1, 201843410000097501000
Tuesday, January 1, 2019782200000118590000
Wednesday, January 1, 20201119900000169802000
Friday, January 1, 202124375000007491000
Saturday, January 1, 202215604000008799000
Sunday, January 1, 20231815800000253598000
Monday, January 1, 20241970500000
Loading chart...

Data in motion

Exploring Cost Efficiency in Biotech Giants: Regeneron vs. Xencor

In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. Regeneron Pharmaceuticals, Inc. and Xencor, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Regeneron, a leader in the industry, has seen its cost of revenue grow by approximately 785% over this period, peaking in 2021. In contrast, Xencor's cost of revenue, while significantly lower, has experienced a more modest increase of around 1,270%, with a notable spike in 2023. This divergence highlights Regeneron's expansive growth strategy, while Xencor's leaner operations suggest a focus on efficiency. The data underscores the importance of strategic financial management in sustaining competitive advantage in the biotech sector. As the industry evolves, these insights provide a window into the operational strategies of two influential players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025